secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2026-10-15T10:10:45+00:00
Accession:  0001493152-26-047090
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Interpace Biosciences prelim Q3 2026 revenue $10.1M-$10.4M, up ~15-18% YoY
--------------------------------------------------------------------------

- Preliminary unaudited Q3 2026 revenue expected to range $10.1 million to $10.4 million.
- Expected ~11%-14% quarter-over-quarter growth from $9.1 million in Q2 2026 and ~15%-18% year-over-year growth from $8.8 million in Q3 2025.
- Results are preliminary and subject to quarter-end closing procedures and review by the company's independent registered public accounting firm.
- Press release furnished as Exhibit 99.1; full Q3 2026 financial results expected to be reported at a later date.
- Release references a free writing prospectus related to an offering with a registration statement filed with the SEC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315226047090/0001493152-26-047090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315226047090/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-047090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer